Serum platelet factor 4 is a promising predictor in newly diagnosed patients with multiple myeloma treated with thalidomide and VAD regimens.

CONCLUSIONS: We speculate serum PF4 is a promising response and prognostic factor in newly diagnosed MM treated with thalidomide and VAD regimens. PMID: 30890040 [PubMed - in process]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research